Advancing Choice in HIV Prevention

In recent weeks, important new resources for advancing choice in HIV prevention have been announced. Don’t miss these highlights from the field. They point to an HIV response in transition, and help to define the role advocacy must play. As policy, practice and budgets strive to keep up with advances in research, advocacy around choice becomes a cross-cutting priority—so that the promise of new options in HIV prevention won’t be squandered in siloed programs, or by poorly-planned supply chains, or because of disconnected policy decisions. People have diverse needs and face complex challenges; ending HIV depends on finding the option that works best for each individual.  

The Choice Manifesto 

Image

The African Women’s HIV Prevention Community Accounability Board (AWPCAB) launched the HIV Prevention Choice Manifesto, calling for increased political and financial support to ensure every proven method of HIV prevention is integrated into the HIV response, so that all women who need prevention will have access to the options that will make prevention possible for them. At the launch event in Kampala, UNAIDS Executive Director Winnie Byanyima gave a keynote address in support of the Manifesto’s call for all stakeholders to commit to the budgets and strategies that will make choice possible.  

“I congratulate you for the HIV Prevention Choice Manifesto. It’s about pushing everyone towards people-centered, women-centered and women-led approaches to HIV prevention. You have fought with your lives to get here. You are fearless feminists. Women must lead for themselves.” – Winnie Byanyima, UNAIDS Executive Director

Learn more about the HIV Prevention Choice Manifesto and other advocacy resources for choice in our latest AVAC blog, Reclaiming Choice: The launch of the HIV Prevention Choice Manifesto and what that means.  

The Dual Prevention Pill (DPP) 

The DPP Consortium created a multiyear strategy to frame priorities and next steps in the development and delivery of the dual prevention pill (DPP), which is being developed to prevent HIV and unintended pregnancy. This multipurpose prevention technology (MPT) combines oral PrEP with an oral contraceptive. The updated strategy consolidates two years of progress toward preparing the field for new MPTs. The strategy addresses additions to the MPT pipeline, the potential role of the private sector in delivering a future DPP, recommendations for provider counseling on the use of the DPP, market research on potential DPP users, the latest analysis on cost, and more.

Stay tuned for more resources and updates to come on the DPP, the Choice Manifesto, and tools for connecting choice to HIV prevention, ending the epidemic and the role of choice in global health equity in HIV, and beyond.

The Architecture for Pandemic Prevention, Preparedness, & Response (PPPR): Views from Civil Society Leaders on the UN High Level Meetings (Guest Essay)

AVAC’s Executive Director along with partners from the Coalition of Advocates for Global Health and Pandemic Preparedness penned an essay to make the case of meaningful investment in Pandemic Preparedness while referencing continued failures of the COVID-19 pandemic. Read the full essay here.

PEPFAR at 20: Keeping the promise

Our latest episode of Px Pulse is out, PEPFAR: Keeping the promise.  

PEPFAR is one of the greatest US foreign policy and global development achievements of the century. The program has saved upwards of 25 million lives since it launched in 2003. But as PEPFAR marks its 20th anniversary, it’s also fighting for its future.  

The US Congress needs to reauthorize PEPFAR for another five years by September 30 and reaffirm its commitment to this lifesaving program. Until a couple of months ago, most in global health and development expected smooth sailing for a five-year reauthorization of the program, as has happened throughout the past 20 years. PEPFAR has enjoyed deep and broad bipartisan support since its founding. Evangelical Christians, staunch conservatives and progressive liberals, Democrats and Republicans, HIV activists, civil society advocates and public health leaders have all championed PEPFAR, year in and year out. But a handful of Republicans, including past PEPFAR allies, are pulling reauthorization into high-stakes partisan politics. 

In this episode, Px Pulse talks to some of the people who put PEPFAR dollars into action and to global health leaders who explain why PEPFAR’s approach has been so effective, and what’s at stake in this debate. 

Tune in to hear: 

    Ilda Kuleba from Mothers 2 Mothers talks about the impact of PEPFAR on their work across 10 countries, training and employing HIV positive mothers as peer healthcare workers. 

    Dr. James Mukabi of World Vision’s Kenya program talks about how this Christian relief organization has changed the lives of thousands of orphans and other populations who are vulnerable to HIV.  

    Tom Hart, President of the ONE Campaign, which was co-founded by the rock star Bono, to be an early champion of PEPFAR and other poverty fighting efforts talks about PEPFAR’s accomplishments at the global level and what’s next as Congress debates reauthorizing the program.

    PEPFAR’s supporters have a job to do, to make sure everyone understands that the world has a lot to lose if PEPFAR is weakened and so, so much to gain if US policymakers unite in their support. We hope you will listen and pass on the episode, download the resources and, most especially, add your voice in support of PEPFAR.

      Announcing the New AVAC.org and Digital Resources

      We are delighted to share the new and improved AVAC.org! On our new site, you can easily access all the great data, policy analysis, tools and resources that you’ve come to expect from AVAC, including our much-loved infographicspodcastsWeekly NewsDigest and Pandemic Watchwebinarsresearch literacy materials and so much more! 
       
      The updated AVAC.org also reflects the expanded vision and practice of our dynamic programs. AVAC will always work to accelerate ethical development and equitable delivery of effective HIV prevention options. But, we also know that responding to HIV and preparing for future pandemics requires a comprehensive, integrated, and sustained response that is rights-based, people-centered and evidence-informed.
       
      To AVAC, this means connecting the dots between HIV prevention, sexual and reproductive health and rights, pandemic preparedness, strengthened health systems, research engagement and community leadership. It means recognizing that resilience in global health requires us to confront the threats posed by disparities in access, entrenched stigma, discrimination, criminalizing key populations and inadequate responses to other sexually transmitted infections.

      Visit the new AVAC.org for resources, tools and analysis that make these connections as we continue to track and translate the field, including:

      • Information on the entire pipeline of biomedical prevention strategies being investigated today
      • Our projects, which showcase the incredible partnerships and collaboration that underpin everything we do
      • Our podcast, PxPulse, which will deepen your knowledge and help you “check the pulse” of this fast-paced field and the urgent challenges still ahead
      • PxWire our quarterly update on where we are in biomedical prevention research
      • Our HIV clinical trials database, where you can find details on all biomedical prevention trials and our broader resource database containing fact sheets, infographics, blog posts and more on HIV prevention and the broader issues surrounding global health equity
      • Links to our newsletters—Pandemic WatchWeekly NewsDigest, and our Advocates Network

      And be sure to check out three vital AVAC resources that give you all the information you need on PrEP accessSTI vaccine and diagnostics R&D and HIV prevention R&D funding.

      We are immensely proud to share these resources with you. We hope these tools and analyses will help to power your advocacy, accelerate ethical development and equitable delivery of effective HIV prevention options, and advance global health equity.

      How do People Who Use/Inject Drugs Intersect with PrEP Research and Service Delivery?

      On Wednesday, September 6, The Choice Agenda (TCA), the International Network of People Who Use Drugs (INPUD) and our wonderful expert speakers discussed the health and wellness priorities of people who use/inject drugs, and how these communities (“key populations”) intersect across PrEP research, development, and implementation activities. They highlighted critical gaps in the PrEP agenda, underscore opportunities for improvement, and share strategies for better inclusion, representation and meaningful engagement.

      Speakers: John Kimani, Kenya Network of People Who Use Drugs (KeNPUD) Dr. Sunil Solomon, Johns Hopkins University, Dr. Tetiana Kaleeva

      ** With special thanks to WHO, this webinar will offer simultaneous Ukrainian translation.**

      Recording / Slides / Resources

      PEPFAR at 20: Keeping the promise

      2023 is a big year for PEPFAR. Considered one of the greatest US foreign policy and global development achievements of the century, the program has saved upwards of 25 million lives since it launched in 2003. But PEPFAR is marking its 20th anniversary while fighting for its future.  

      Its authorization expires September 30. Until a couple of months ago, most expected smooth sailing in the US Congress for a five-year reauthorization of the program. PEPFAR has enjoyed deep and broad bipartisan support since its founding. Evangelical Christians, staunch conservatives, DC Democrats, progressive HIV activists, and public health leaders have championed PEPFAR, year in and year out. But a handful of Republicans, including past PEPFAR allies, are pulling reauthorization into high-stakes partisan politics. 

      In this episode, Px Pulse talks to some of the people who put PEPFAR dollars into action and to global health leaders who explain why PEPFAR’s approach has been so effective, and what’s at stake in this debate. 

      Tune in to hear:

      • Ilda Kuleba from Mothers 2 Mothers talks about the impact of their work across 10 countries, training and employing HIV positive mothers as peer healthcare workers.
      • Dr. James Mukabi of World Vision’s Kenya program talks about how this Christian relief organization has changed the lives of thousands of orphans and other populations who are vulnerable to HIV. 
      • Tom Hart, President of the One Campaign, which was founded by the rock star Bono, to be an early champion of PEPFAR and other poverty fighting efforts talks about PEPFAR’s accomplishments at the global level and what’s next as congress debates reauthorizing the program.

      Links:

      Advocacy Resources:

      Media:

      AVAC 2024 Advocacy Fellows Applications Now Open!

      Application Deadline: 2 October 2023

      AVAC is thrilled to invite applications for the 2024 Advocacy Fellows Program. Fellows accepted into the program, will mark the 13th cohort of this program. Read further to explore the history of the program, learn about new features for 2024, find application details, and register for upcoming informational sessions.

      Download Application Materials HereApplication deadline: 2 October 2023

      About AVAC’s Advocacy Fellows Program

      Achieving successful HIV prevention relies on programs and research shaped by communities and grounded by their needs and priorities. Skilled and informed community advocates drive this process. AVAC’s Advocacy Fellows Program expands and strengthens the capacity of civil society advocates and organizations to monitor, support and help shape HIV prevention research and rapid rollout of new effective interventions in low- and middle-income countries facing substantial HIV burdens.

      The program provides intensive support to emerging and mid-career advocates to execute advocacy projects addressing locally identified gaps and priorities. Fellows receive comprehensive training, financial backing, and technical assistance to strategize and execute a targeted 18-month project hosted by an organization within their country.

      In its 15-year history, 85 Fellows and 75 partner organizations across 15 countries have participated in the program. They have influenced policy, championed community perspectives, strengthened healthcare systems, demystified HIV prevention research, advocated for fairness and transparency on local, regional, and global scales and now lead many national and regional organizations. Discover more about the program’s impact here. As the 2022 Fellows conclude their Fellowships, learn more about their projects and achievements here.

      What’s New in 2024

      While HIV biomedical prevention advocacy remains central, we encourage projects with a strong focus on health equity, structural considerations, and links to TB, STIs, and sexual and reproductive health and rights. Advocacy projects related to pandemic prevention, preparedness and response are also welcomed.

      Eligibility

      • Emerging or mid-career community leaders and advocates who want to advance their advocacy skills and advocate for HIV, SRHR, STI, TB, and pandemic prevention and preparedness.
      • Individuals with experience or education in HIV or public health, or in advocacy for key populations (e.g., sex workers, LGBTQIA+ individuals, pregnant individuals, people who use drugs) or for social and economic justice.
      • Based in low- and middle-income countries with substantial HIV burdens and ongoing HIV prevention research or introduction of new interventions.
      • Please note that for 2024 fellowships, priority focus lies in Eastern and Southern Africa.

      Proficient in written and spoken English.

      Application Process

      Learn More

      Applications are due by 2 October 2023, and 2024 Fellowships will run from April 2024 through September 2025.

      Spread the Word

      Help us reach potential advocates by sharing this information within your networks.

      We look forward to receiving your application and making a positive impact together.

      Avac Event

      How do People Who Use/Inject Drugs Intersect with PrEP Research and Service Delivery?

      On Wednesday, September 6, please make plans to join The Choice Agenda (TCA), the International Network of People Who Use Drugs (INPUD) and our wonderful expert speakers to discuss the health and wellness priorities of people who use/inject drugs, and how these communities (“key populations”) intersect across PrEP research, development, and implementation activities. They will highlight critical gaps in the PrEP agenda, underscore opportunities for improvement, and share strategies for better inclusion, representation and meaningful engagement.

      Speakers: John Kimani, Kenya Network of People Who Use Drugs (KeNPUD) Dr. Sunil Solomon, Johns Hopkins University, Ukrainian Provider

      ** With special thanks to WHO, this webinar will offer simultaneous Ukrainian translation. **

      Press Release

      AVAC Applauds the Selection of Dr. Jeanne Marrazzo as New Director of NIAID  

      Wednesday, August 2, 2023 

      AVAC enthusiastically applauds the selection of Jeanne Marrazzo, MD, to serve as the new director of the NIH’s National Institute of Allergy and infectious Disease (NIAID). Dr. Marrazzo brings unparalleled leadership and research expertise to this pivotal role at NIAID, which oversees some of the largest investments to advance research on HIV and sexually transmitted infections in the world, at such a critical moment in global health science and politics. 

      “Jeanne has been a pioneer in both HIV prevention and STI research and advocacy for many years. This news of her selection as NIAID Director just does not get any better,” said Mitchell Warren, AVAC’s Executive Director. “Given her distinguished career, NIAID’s selection signals a commitment to pursuing a research agenda that is aimed squarely at defeating HIV while safeguarding principles that advance global health equity. Moreover, her appointment reflects the important intersection of science, policy, communications and advocacy that has defined her career thus far.” 

      “Perhaps most importantly, her longtime championship of community engagement and person-centered research provides a fantastic foundation for this role,” said Manju Chatani-Gada, AVAC’s Director for Partnerships & Capacity Strengthening. “She has always been accessible and provided time, mentorship and support to civil society advocates in breaking down and interpreting science. Ultimately, it is not just what science gets supported at NIAID, but how the science happens and how it is communicated, and Jeanne is the right leader at the right time to build on Dr. Fauci’s legacy.” 

      Dr. Marrazzo’s research included landmark investigations of pre-exposure prophylaxis (PrEP) for cisgender women as well as discovery and implementation science research focused on complex issues including hormonal contraception and HIV, antimicrobial resistance in gonorrhea, and other efforts especially as they effect women’s health and livelihoods and exacerbate the impact of infectious diseases. She provided pioneering leadership of the Microbicide Trials Network’s groundbreaking Vaginal and Oral Interventions to Control the Epidemic (VOICE) study, one of the most complex HIV prevention studies ever designed and conducted. 

      “Jeanne is a remarkable physician, researcher and advocate. We are so optimistic about her ability to connect the dots—between HIV prevention, sexual and reproductive health, and pandemic preparedness, and help solve for the threats of disparities in access, stigma, discrimination and criminalization of key populations,” Warren added.  

      Dr. Marrazzo will be the first new director of NIAID in nearly 40 years and the first woman in this position. She will also be the first openly gay director of any institute at the NIH. The position was held by Dr. Anthony Fauci, whose vision, passion and commitment to ending the AIDS epidemic and advancing global health research has been an inspiration to AVAC and to so many. Dr. Marrazzo is expected to assume the post as NIAID Director later this year. 

      ###

      About AVAC: AVAC is an international non-profit organization that leverages its independent voice and global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention options, as part of a comprehensive and integrated pathway to global health equity. Follow AVAC on Twitter @HIVpxresearch; find more at www.avac.org and www.prepwatch.org.

      Who’s Driving This Ship?

      Over the last year, governments and health leaders have been working to restructure the global health system to ensure pandemic prevention, preparedness, and response. The COVID-19 pandemic forced a reckoning, exposing a deeply inequitable global health system, and advocates, civil society, health workers and leaders representing southern populations, have called on governments to rewrite the world’s contract – in particular, asking Global North governments to finally give up some power and, in the service of preventing and preparing for pandemic threats, agree to join a system that is equitable and aims to prevent health threats everywhere and prepare everyone.

      At AVAC, we have put a lot of hope in the processes of the Pandemic Accord, the UN High-Level Meeting (HLM) on Prevention, Preparedness, and Response (PPPR), and the development of a medical countermeasures (MCM) platform. (To understand how these three efforts fit together, see AVAC’s Advocate’s Guide to PPPR.) However, sadly, and in honesty, predictably, many high-income countries seem unwilling to alter the status quo. We see four main sticking points that come down to whether these countries will relinquish control:

      Data sharing

      Global agreements to share pathogen data and genomic sequencing in the event of a novel pandemic threat represent one of the most important areas of negotiation in these processes. Understandably, many countries are keen to ensure they can have access to data on newly discovered pathogens so they can create a vaccine or treatment as soon as possible and protect their citizens. But since research, manufacturing capacity, and resources are concentrated in the Global North, such an agreement presents a bad deal for countries in the Global South. Such an agreement would require them to share the data they have access to, but continue to be last in line for the vaccines or other interventions that get developed from that data.  To add insult to injury, they may well be punished for sharing it, as was the case when the Republic of South Africa shared data on the Omicron mutation of COVID-19 and then saw Global North countries subsequently block entry to their citizens.

      But so far, the countries pushing to secure agreements on data sharing refuse to grapple with these concerns. They have not budged and remain unwilling to support language that would ensure access to the beneficial medical countermeasures and that are developed from shared data. While the potential for open science and a platform for data sharing holds promise, these efforts will predictably result in simply exacerbating inequalities unless these agreements beef up commitments around equity. Negotiations on this issue have been tense, with no resolution in sight.

      R&D

      The concentration of research capacity in the Global North represents another major hurdle. Because the majority of resources for R&D are held by either Northern governments or corporations headquartered in the North, their priorities dictate the answers to questions such as which pathogens, what intervention to pursue, and what populations to help first. For example, $35.8B was spent on medical research worldwide in 2022, but only $3.95B was invested in R&D on diseases with an outsized impact on people living in the global south (including HIV, tuberculosis, and malaria) in 2020. Some governments, like the countries in the ‘Group on Equity’, are calling for more distributed investments, more collective resources dedicated to pathogens of pandemic potential (such as those in the Africa CDC’s priority list), and agreed-upon standards for the diversity of populations that must be included in clinical trials. Negotiations are ongoing, with a lot of opposition coming from pharmaceutical corporations.

      MCM platform

      We are quite concerned with the current process of developing an MCM platform that has been proposed by the G7 and G20, along with WHO’s support. The stated aim of the platform is to coordinate equitable development, distribution, and delivery of medical countermeasures for pandemics, including vaccines, therapeutics, diagnostics, and other tools, and to implement the platform in ‘peacetime’ before the next pandemic hits so we’re ready. So far, however, the development process has been largely driven by G7 and G20 countries, both because it will take investment from these countries and because less-resourced countries simply do not have capacity to engage in another PPPR-related process in addition to the Pandemic Accord and UN HLM. Discussions between civil society and country representatives are not happening – while WHO and different agencies have held official meetings with countries, civil society have been relegated to separate discussions. Some global health leaders, from both countries and agencies, have expressed a desire to leave ‘thorny’ issues out of it. But public health advocates and civil society insist that these issues such as intellectual property, clinical trials and R&D prioritization, allocation, the inclusion of marginalized groups, and governance must be considered now before the platform is stood up. It’s unclear who is making the decisions here, but it is certainly not those most burdened by disease.

      Financing

      The Pandemic Accord draft and the draft UN Declaration on PPPR include few concrete references to PPPR financing targets or finance reform. One of those few is the mention of new-to-the-field Pandemic Fund as a primary resourcing vehicle. This apparent reliance on the Pandemic Fund raises serious questions, as the Fund has offered just $300M in the first round of funding. PPPR agreements that defer finance commitments to the Fund are misguided at best and reveal a lack of ambition to effectively confront pandemic threats. The world currently needs to turn this ship around. Pandemic preparedness must not be an afterthought, a half-hearted boondoggle that only serves the interest of rich countries. All of the issues raised here, in addition to the need to upgrade and expand surveillance systems, increase and strengthen the health workforce, and build up regional manufacturing capacity, need resources to be implemented. On top of those pressing needs, many of the countries that are in most need of investment in pandemic preparedness are straining to manage enormous debt burdens imposed by wealthy countries.  Advocates are asking that governments include, in the UN Declaration on PPPR and Pandemic Accord, reference to existing mechanisms such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria (currently the largest funder of PPPR worldwide), the WHO Contingency Fund for Emergencies, and the IMF Resilience and Sustainability Trust as existing vehicles for pandemic preparedness resourcing. PPPR will advance equitably and effectively, and less resources will be needed, if countries commit to leveraging what has already been built in the ongoing responses to HIV, tuberculosis, and malaria. PPPR must learn from twenty years of demonstrated success fighting pandemic and epidemic threats.

      So who is driving this ship?

      It appears that those who have historically held control have not learned their lesson after yet another global pandemic that abandoned poorer countries and left all of us more vulnerable to the next pandemic. Instead of facing the reality that disease knows no borders and resetting the global health system, those who hold the purse strings seem content to continue with the status quo – hoarding the fruits of science, reinforcing exclusive and hegemonic systems, consolidating power among the few, and keeping health systems fragmented and underfunded. It’s an upside-down system – with those most secure and least in touch with the impact of their decisions in charge. The PPPR ship must be driven by those most burdened by pandemic threats and ongoing epidemics, or we will most certainly face another devastating pandemic and decision-makers will wish they turned it around now.